Ovid Therapeutics receives FDA rare paediatric disease designation for OV101 for the treatment of Angelman syndrome

19 June 2020 - Ovid Therapeutics  today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease ...

Read more →

Dicerna receives rare paediatric disease designation from U.S. FDA for nedosiran for the treatment of primary hyperoxaluria

18 June 2020 - Dicerna Pharmaceuticals today announced that the U.S. FDA has granted rare paediatric disease designation for nedosiran, ...

Read more →

FDA takes additional action to harness real world data to inform COVID-19 response efforts

18 June 2020 - Today the U.S. Food and Drug Administration has taken an additional step in harnessing real-world data to ...

Read more →

Clinical trial costs to develop a new drug may actually be rather modest — or so one study suggests

18 June 2020 - For years, the pharmaceutical industry has maintained that the costs to develop medicines accounts for rising ...

Read more →

Linnaeus Therapeutics granted U.S. FDA fast track designation for LNS8801 for the treatment of patients with metastatic or unresectable melanoma who have progressed on anti-PD-1/L1 therapy

18 June 2020 - Company Conducting Ongoing Phase 1/2 Study of LNS8801. ...

Read more →

FDA granted accelerated approval to tazemetostat for follicular lymphoma

18 June 2020 - Today the Food and Drug Administration granted accelerated approval to tazemetostat (Tazverik, Epizyme), an EZH2 inhibitor, ...

Read more →

FDA approves first therapy for rare disease that causes low phosphate blood levels, bone softening

18 June 2020 - Today, the U.S. Food and Drug Administration approved Crysvita (burosumab-twza) injection to treat patients age two and ...

Read more →

TG Therapeutics completes rolling submission of new drug application to the U.S. FDA for umbralisib as a treatment for patients with previously treated marginal zone lymphoma or follicular lymphoma

17 June 2020 - TG Therapeutics today announced the completion of the rolling submission of a new drug application to the ...

Read more →

Chi-Med announces fruquintinib granted U.S. FDA fast track designation for metastatic colorectal cancer

18 June 2020 - Hutchison China MediTech today announces that the U.S. FDA has granted fast track designation for the development ...

Read more →

Identifying the risks of unproven regenerative medicine therapies

17 June 2020 - In the middle of the coronavirus disease 2019 public health response, many priorities are currently competing for ...

Read more →

Ipsen receives FDA fast track designation for liposomal irinotecan (Onivyde) as a first-line combination treatment for metastatic pancreatic cancer

17 June 2020 - Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at ...

Read more →

FDA approves pembrolizumab for adults and children with TMB-H solid tumours

17 June 2020 - On 16 June  2020, the FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment ...

Read more →

A mad scramble to stock millions of malaria pills, likely for nothing

16 June 2020 - Before the F.D.A. withdrew its waiver to stockpile the drugs as coronavirus treatments, the Trump administration had ...

Read more →

An ‘America first’ pharma supply chain sounds good. But it won’t work.

17 June 2020 - With a stroke of the president’s Executive Order pen, the Trump administration awarded a $354 million, ...

Read more →

Most coronavirus tests cost about $100. Why did one cost $2,315?

16 June 2020 - U.S. health care prices are unregulated, opaque and unpredictable. When Congress required insurers to cover COVID-19 testing, ...

Read more →